Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 37 for your search:
Drug:
oblimersen sodium
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase II/III Randomized Study of Docetaxel With or Without Oblimersen (Bcl-2 Antisense Oligonucleotide; G3139 ) in Patients With Previously Treated Non-Small Cell Lung Cancer
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
GENTA-GN304
, NCI-G01-2046, UCLA-0301058, NCT00030641
2.
Phase III Randomized Study of Dacarbazine With or Without Oblimersen (G3139) in Patients With Advanced Malignant Melanoma
Phase:
Phase III
Type:
Treatment
Status:
Closed
Age:
Any age
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
GENTA-GM301
, UCLA-0207109, NCT00016263
3.
Phase III Randomized Study of Dexamethasone With or Without Oblimersen in Patients With Relapsed or Refractory Multiple Myeloma
Phase:
Phase III
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
GENTA-GMY302
, UF-G-29-2001, NCT00017602
4.
Phase III Randomized Study of Fludarabine and Cyclophosphamide With or Without Oblimersen (G3139, Genasense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Phase:
Phase III
Type:
Treatment
Status:
Closed
Age:
Over 18
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
GENTA-GL303
, UCLA-0104008, NCT00024440
5.
Phase III Randomized Study of Daunorubicin and Cytarabine With or Without Oblimersen in Older Patients With Previously Untreated Acute Myeloid Leukemia
Phase:
Phase III
Type:
Treatment
Status:
Completed
Age:
60 and over
Sponsor:
NCI
Protocol IDs:
CALGB-10201
, NCT00085124
6.
Trial of Dacarbazine With or Without Genasense in Advanced Melanoma
Phase:
Phase III
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
AGENDA
, GM307, NCT00518895
7.
Phase I/II Study of Oblimersen With Docetaxel in Patients With Androgen-Independent Prostate Cancer or Other Advanced Solid Tumors (Summary Last Modified 12/2001)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
MSKCC-97096
, GENTA-G3139-97/01, NCI-G97-1337, NCT00003103
8.
Phase I/II Study of Augmerosen and Irinotecan in Patients With Metastatic or Recurrent Colorectal Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
SACI-IDD-98-32
, UTHSC-IDD-98-32, NCI-T98-0094, NCT00004870, T98-0094
9.
Phase I/II Study of Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Patients With Recurrent Small Cell Lung Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UCCRC-10017
, NCI-T98-0091, NCT00005032, T98-0091
10.
Phase I/II Study of Oblimersen in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
GENTA-GL208
, MDA-ID-00337, NCT00021190
11.
Phase I/II Study of Oblimersen, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Patients With Advanced Colorectal Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
SACI-IDD-02-23
, NCI-5793, NCT00055822, 5793
12.
Phase I/II Study of Oblimersen in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MAYO-MC0285
, NCI-5826, 5826, NCT00062244
13.
Phase II Study of Oblimersen in Combination With Doxorubicin and Docetaxel in Patients With Metastatic or Locally Advanced Breast Cancer (Phase I portion of the study completed as of 8/16/04)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MDA-DM-02700
, NCI-6023, NCT00063934, 6023
14.
Phase I/II Pilot Study of Oblimersen, Cisplatin, and Fluorouracil in Patients With Advanced Esophageal, Gastroesophageal Junction, or Gastric Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Closed
Age:
Over 18
Sponsor:
NCI
Protocol IDs:
AECM-0266
, NCI-5835, AECM-0302032, NCT00064259, 5835
15.
Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
GL217
, NCT00078234
16.
Phase I/II Study of Oblimersen in Combination With Rituximab, Ifosfamide, Carboplatin, and Etoposide in Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UCCRC-12975A
, 6243, NCI-6243, NCT00086944
17.
Phase II Study of Oblimersen and Gemtuzumab Ozogamicin in Elderly Patients With Relapsed Acute Myeloid Leukemia
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
60 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
GENTA-GA210
, UCCRC-10928, NCT00017589
18.
Phase II Randomized Study of Carboplatin and Etoposide With or Without Oblimersen in Patients With Extensive Stage Small Cell Lung Cancer
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CALGB-30103
, NCT00042978
19.
Phase II Study of Oblimersen and Doxorubicin in Patients With Advanced Hepatocellular Carcinoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
PMH-PHL-011
, NCI-5798, NCT00047229, 5798
20.
Phase II Study of Oblimersen and Imatinib Mesylate in Patients With Imatinib Mesylate-Resistant Chronic Myelogenous Leukemia
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
15 and over
Sponsor:
NCI
Protocol IDs:
CALGB-10107
, NCT00049192
21.
Phase II Study of Oblimersen and Rituximab in Patients With Recurrent B-Cell Non-Hodgkin's Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MDA-ID-02148
, NCI-5808, NCT00054639, 5808
22.
Phase II Study of Oblimersen and Interferon alfa in Patients With Metastatic Renal Cell Cancer
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CCC-PHII-42
, CHNMC-PHII-42, NCI-5828, NCT00059813, 5828
23.
Phase II Study of Oblimersen in Patients With Metastatic or Recurrent Merkel Cell Carcinoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MSKCC-03105
, NCI-5907, 5907, NCT00079131
24.
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 to 59
Sponsor:
NCI, Other
Protocol IDs:
CDR0000356049
, SWOG-S0349, NCT00080847
25.
Phase II Randomized Study of Docetaxel With or Without Oblimersen in Patients With Hormone-Refractory Adenocarcinoma of the Prostate
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
EORTC-30021
, AVENTIS-AVE3139E/2501, NCT00085228
Select All on Page
1
Help with Results
